124 related articles for article (PubMed ID: 30259401)
21. Development of a stable liquid formulation of live attenuated influenza vaccine.
White JA; Estrada M; Flood EA; Mahmood K; Dhere R; Chen D
Vaccine; 2016 Jul; 34(32):3676-83. PubMed ID: 27155495
[TBL] [Abstract][Full Text] [Related]
22. Pulmonary delivery of influenza vaccine formulations in cotton rats: site of deposition plays a minor role in the protective efficacy against clinical isolate of H1N1pdm virus.
Bhide Y; Tomar J; Dong W; de Vries-Idema J; Frijlink HW; Huckriede A; Hinrichs WLJ
Drug Deliv; 2018 Nov; 25(1):533-545. PubMed ID: 29451040
[TBL] [Abstract][Full Text] [Related]
23. Developments in the formulation and delivery of spray dried vaccines.
Kanojia G; Have RT; Soema PC; Frijlink H; Amorij JP; Kersten G
Hum Vaccin Immunother; 2017 Oct; 13(10):2364-2378. PubMed ID: 28925794
[TBL] [Abstract][Full Text] [Related]
24. Stabilization of HAC1 influenza vaccine by spray drying: formulation development and process scale-up.
Zhu C; Shoji Y; McCray S; Burke M; Hartman CE; Chichester JA; Breit J; Yusibov V; Chen D; Lal M
Pharm Res; 2014 Nov; 31(11):3006-18. PubMed ID: 24858396
[TBL] [Abstract][Full Text] [Related]
25. Biodegradable nanoparticle delivery of inactivated swine influenza virus vaccine provides heterologous cell-mediated immune response in pigs.
Dhakal S; Hiremath J; Bondra K; Lakshmanappa YS; Shyu DL; Ouyang K; Kang KI; Binjawadagi B; Goodman J; Tabynov K; Krakowka S; Narasimhan B; Lee CW; Renukaradhya GJ
J Control Release; 2017 Feb; 247():194-205. PubMed ID: 28057521
[TBL] [Abstract][Full Text] [Related]
26. Long-term stability of influenza vaccine in a dissolving microneedle patch.
Mistilis MJ; Joyce JC; Esser ES; Skountzou I; Compans RW; Bommarius AS; Prausnitz MR
Drug Deliv Transl Res; 2017 Apr; 7(2):195-205. PubMed ID: 26926241
[TBL] [Abstract][Full Text] [Related]
27. Protective efficacy of intranasal cold-adapted influenza A/New Caledonia/20/99 (H1N1) vaccines comprised of egg- or cell culture-derived reassortants.
Palker T; Kiseleva I; Johnston K; Su Q; Toner T; Szymkowiak C; Kwan WS; Rubin B; Petrukhin L; Wlochowski J; Monteiro J; Kraiouchkine N; DiStefano D; Rudenko L; Shaw A; Youil R
Virus Res; 2004 Oct; 105(2):183-94. PubMed ID: 15351492
[TBL] [Abstract][Full Text] [Related]
28. Spray-Dried Influenza Antigen with Trehalose and Leucine Produces an Aerosolizable Powder Vaccine Formulation that Induces Strong Systemic and Mucosal Immunity after Pulmonary Administration.
Sou T; Morton DA; Williamson M; Meeusen EN; Kaminskas LM; McIntosh MP
J Aerosol Med Pulm Drug Deliv; 2015 Oct; 28(5):361-71. PubMed ID: 25714115
[TBL] [Abstract][Full Text] [Related]
29. Feasibility of intranasal delivery of thin-film freeze-dried, mucoadhesive vaccine powders.
Yu YS; AboulFotouh K; Xu H; Williams G; Suman J; Cano C; Warnken ZN; Wu KC; Williams RO; Cui Z
Int J Pharm; 2023 Jun; 640():122990. PubMed ID: 37127138
[TBL] [Abstract][Full Text] [Related]
30. A comparison between spray drying and spray freeze drying to produce an influenza subunit vaccine powder for inhalation.
Saluja V; Amorij JP; Kapteyn JC; de Boer AH; Frijlink HW; Hinrichs WL
J Control Release; 2010 Jun; 144(2):127-33. PubMed ID: 20219608
[TBL] [Abstract][Full Text] [Related]
31. Generation of a High-Growth Influenza Vaccine Strain in MDCK Cells for Vaccine Preparedness.
Kim EH; Kwon HI; Park SJ; Kim YI; Si YJ; Lee IW; Kim SM; Kim SI; Ahn DH; Choi YK
J Microbiol Biotechnol; 2018 Jun; 28(6):997-1006. PubMed ID: 29642288
[TBL] [Abstract][Full Text] [Related]
32. Consecutive inoculations of influenza virus vaccine and poly(I:C) protects mice against homologous and heterologous virus challenge.
Moriyama M; Chino S; Ichinohe T
Vaccine; 2017 Feb; 35(7):1001-1007. PubMed ID: 28111142
[TBL] [Abstract][Full Text] [Related]
33. A boosting skin vaccination with dissolving microneedle patch encapsulating M2e vaccine broadens the protective efficacy of conventional influenza vaccines.
Zhu W; Pewin W; Wang C; Luo Y; Gonzalez GX; Mohan T; Prausnitz MR; Wang BZ
J Control Release; 2017 Sep; 261():1-9. PubMed ID: 28642154
[TBL] [Abstract][Full Text] [Related]
34. Entrapment of H1N1 Influenza Virus Derived Conserved Peptides in PLGA Nanoparticles Enhances T Cell Response and Vaccine Efficacy in Pigs.
Hiremath J; Kang KI; Xia M; Elaish M; Binjawadagi B; Ouyang K; Dhakal S; Arcos J; Torrelles JB; Jiang X; Lee CW; Renukaradhya GJ
PLoS One; 2016; 11(4):e0151922. PubMed ID: 27093541
[TBL] [Abstract][Full Text] [Related]
35. Stability of collapse lyophilized influenza vaccine formulations.
Anamur C; Winter G; Engert J
Int J Pharm; 2015 Apr; 483(1-2):131-41. PubMed ID: 25660049
[TBL] [Abstract][Full Text] [Related]
36. Safety and immunogenicity in man of a cell culture derived trivalent live attenuated seasonal influenza vaccine: a Phase I dose escalating study in healthy volunteers.
Heldens J; Hulskotte E; Voeten T; Breedveld B; Verweij P; van Duijnhoven W; Rudenko L; van Damme P; van den Bosch H
Vaccine; 2014 Sep; 32(39):5118-24. PubMed ID: 24858566
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the immunogenicity and protective effects of a trivalent chimeric norovirus P particle immunogen displaying influenza HA2 from subtypes H1, H3 and B.
Gong X; Yin H; Shi Y; He X; Yu Y; Guan S; Kuai Z; Haji NM; Haji NM; Kong W; Shan Y
Emerg Microbes Infect; 2016 May; 5(5):e51. PubMed ID: 27222326
[TBL] [Abstract][Full Text] [Related]
38. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
Joseph A; Itskovitz-Cooper N; Samira S; Flasterstein O; Eliyahu H; Simberg D; Goldwaser I; Barenholz Y; Kedar E
Vaccine; 2006 May; 24(18):3990-4006. PubMed ID: 16516356
[TBL] [Abstract][Full Text] [Related]
39. The effect of mucoadhesive excipient on the nasal retention time of and the antibody responses induced by an intranasal influenza vaccine.
Saito S; Ainai A; Suzuki T; Harada N; Ami Y; Yuki Y; Takeyama H; Kiyono H; Tsukada H; Hasegawa H
Vaccine; 2016 Feb; 34(9):1201-7. PubMed ID: 26802605
[TBL] [Abstract][Full Text] [Related]
40. A method of lyophilizing vaccines containing aluminum salts into a dry powder without causing particle aggregation or decreasing the immunogenicity following reconstitution.
Li X; Thakkar SG; Ruwona TB; Williams RO; Cui Z
J Control Release; 2015 Apr; 204():38-50. PubMed ID: 25735896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
